Orchestra BioMed
OBIO

Orchestra BioMed (OBIO) analyst forecast and price target

Recent analyst ratings

FirmActionRatingPrice targetDate
Piper SandlerMaintainedOverweight$10.00 from $9.00Aug 11, 2026
B. Riley SecuritiesMaintainedBuy$10.00 from $12.00May 19, 2026
HC Wainwright & Co.MaintainedBuy$10.00May 14, 2026
BarclaysMaintainedOverweight$13.00 from $12.00May 13, 2026
Chardan CapitalMaintainedBuy$20.00Mar 12, 2026
BarclaysMaintainedOverweight$12.00 from $11.00Jan 9, 2026
TD CowenInitiated CoverageBuy$15.00Dec 10, 2025
Chardan CapitalMaintainedBuy$20.00Nov 13, 2025
BarclaysMaintainedOverweight$11.00 from $12.00Nov 12, 2025
HC Wainwright & Co.MaintainedBuy$10.00 from $12.00Sep 4, 2025
BTIGDowngradedBuy → NeutralAug 20, 2025
Chardan CapitalMaintainedBuy$20.00Aug 13, 2025
Chardan CapitalMaintainedBuy$20.00Aug 7, 2025
Chardan CapitalMaintainedBuy$20.00May 13, 2025
BarclaysMaintainedOverweight$12.00 from $16.00May 5, 2025
Chardan CapitalMaintainedBuy$20.00Apr 22, 2025
HC Wainwright & Co.MaintainedBuy$12.00 from $14.00Apr 4, 2025
Chardan CapitalMaintainedBuy$20.00Apr 1, 2025
BTIGInitiated CoverageBuy$12.00Mar 20, 2025
HC Wainwright & Co.MaintainedBuy$14.00Mar 10, 2025

Frequently asked questions

  • What is the latest analyst rating on OBIO?

    On Aug 11, 2026, Piper Sandler maintained Orchestra BioMed at Overweight with a price target of $10.00.

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.